Clinical Trials Browser

CA-4948 × Genitourinary × 90 days × Clear all

NCT06439836 2026-05-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1 Recruiting

Carcinoma, Transitional Cell